Patients on GLP-1RAs are considered at-risk, meaning they also should: Follow more frequent reexamination intervals Receive individualized risk counseling regarding ocular risks Get collaborative care with providers managing their diabetes and other systemic conditions Doctors of optometry have to be aware, Dr
doi:10.3389/fendo.2018.00058 207
Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight
SUGGESTED USE: As a dietary supplement, take four (4) capsules daily, with a meal and 8 fl oz of water
On April 29, 2025, a press release hailed the Novo Nordisk tie-up for "affordable access" to semaglutide, calling it "high-quality" and "personalized." Dudum said it tackled shortages while "prioritizing safety." The Q1 earnings call echoed this, with Dudum bragging about "innovative partnerships" for consumer choice
The 8 mg dose subgroup had an MD of 28.51 (95% CI: 60.58 to 3.56, P = 0.08), with significant heterogeneity ( P = 0.0003, I 2 = 92%)
